Top biotech investor says Trump's criticism of Pfizer is scaring drug companies from raising prices
Sarissa Capital Management chief investment officer Alex Denner believes President Donald Trump’s criticism of Pfizer is having an impact on how other companies set their prices. “By putting pressure on one particular company, I think all the companies are saying: We don’t want to be Pfizer,” Denner said at the Delivering Alpha Conference. Trump bashed Pfizer and other drugmakers for raising the price of 104 different drugs, arguing that such companies “should be ashamed” for the hikes.